dr. L.C.L.T. (Léon) van Kempen
Clinical Scientist in Molecular Pathology
Telephone:
+31 50 361 5129 (Office)
Staff assistant:
+31 50 361 0020 (Mrs. Annet Bouman - Van der Jagt)
E-mail:
l.van.kempen umcg.nl
Field/Discipline
Expertise
Molecular Pathology in general, but with a focus on melanoma, sarcoma and lung carcinoma.
Biomarker discovery and validation.
Development of diagnostic tools for clinical use.
Quality control and assurance in a clinical diagnostic environment (NEN-EN-ISO15189)
Biomarker discovery and validation.
Development of diagnostic tools for clinical use.
Quality control and assurance in a clinical diagnostic environment (NEN-EN-ISO15189)
Other positions
- Director of Molecular Pathology, Department of Pathology, University Hospital Antwerp, Belgium (as of 01 October 2022)
- EORTC melanoma group - Steering cie. and member of the pathology working group: melanomagroup.eu/site/
- EORTC Pathobiology group - Work group member
- Dutch Workgroup for Hematopathology (NWHP) - Steering cie member : pathology.nl/expertise-groepen/hematopathologie/
- Euroclonality - Member of the quality control work group
- Dutch Society for Pathology (NVVP) member Expertise group Molecular Pathologie
- Assessor - Dutch Accreditation Council (RVA; reimbursements paid to UMCG)
- Editorial Board - Precision Cancer Medicine
- Editorial Board - Cancers
- Lid Stuurgroep Oncology Update Symposium
- Between 2015-2022 Dr. van Kempen has received honoraria from commercial parties paid to the UMCG. Speaker fees: AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, nanoString, Pfizer and Roche. Advisory board: Janssen-Cilag, Merck and Roche. Research funding: Amgen, Bayer, Invitae, Janssen-Cilag, MSD, nanoString and Roche
Last modified:01 March 2024 1.39 p.m.